Immix Biopharma NEXICART-2 Achieves 95% Complete Response Rate
Immix Biopharma announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response - CR -. The NEXICART-2 CR rate is now 95% - 19 out of 20 patients -. All CRs were reached within 1 year of follow-up post-dosing. No relapses have been observed as of today for patients who have reached CR. All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month. The next NEXICART-2 update is expected late September. These results support the company's plan to initiate a multi-center, randomized Phase 3 trial in newly diagnosed AL Amyloidosis patients. AL amyloidosis is a devastating disease where the immune system continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. NXC-201 has been awarded Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy by the FDA, and Orphan Drug Designation by the FDA and in the EU by the EMA.
